Pharmacore secures funding to improve medication regimen reviews in long-term care
New ESW Guide Explains Copilot Studio Agent Pricing and the Controls to Set First
EMH Group modernises resident WiFi across its estate with Purple
TestMu AI Launches New Experience in KaneAI, Turning Recorded Tests into Objectives That Repair Themselves
Sweet Security Launches Virtual Patching to Protect Production Before Permanent Fixes Are Deployed
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting…
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions…
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions…
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation…
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation…
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical…
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical…
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious…
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious…
Breakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications Building innovative internal pipeline…
Breakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications Building innovative internal pipeline…
BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a…
BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a…
Three U.S. clinical trial sites actively screening and enrolling patients Top line data of adrulipase…
Three U.S. clinical trial sites actively screening and enrolling patients Top line data of adrulipase…
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader…